Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4436162
Max Phase: Preclinical
Molecular Formula: C154H250N44O39S7
Molecular Weight: 3566.43
Molecule Type: Unknown
Associated Items:
ID: ALA4436162
Max Phase: Preclinical
Molecular Formula: C154H250N44O39S7
Molecular Weight: 3566.43
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=C(NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H]1CS[C@@H](C)[C@@H]2NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]3CS[C@@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CS[C@@H](C)[C@H](NC(=O)[C@@H]5CSC[C@H](NC(=O)/C(=C/C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(=C)C(=O)N[C@@H](CC(C)C)C(=O)N5)C(=O)N5CCC[C@H]5C(=O)NCC(=O)N4)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N3)[C@@H](C)CC)C(C)C)[C@H](C)SC[C@H](NC2=O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N1)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
Standard InChI: InChI=1S/C154H250N44O39S7/c1-28-75(14)112(159)144(226)173-89(32-5)127(209)185-101-63-240-64-102(186-132(214)96(53-72(8)9)180-124(206)81(20)169-148(230)115(76(15)29-2)193-141(101)223)142(224)197-121-86(25)244-66-103(171-111(203)61-163-143(225)107-43-39-49-198(107)153(121)235)137(219)175-91(41-34-37-47-156)129(211)195-118-83(22)241-65-104(172-110(202)60-162-126(208)92(44-50-238-26)176-131(213)95(52-71(6)7)179-122(204)79(18)167-109(201)59-164-145(118)227)138(220)182-99(56-108(158)200)135(217)191-117(78(17)31-4)150(232)190-114(74(12)13)147(229)177-93(45-51-239-27)128(210)174-90(40-33-36-46-155)130(212)196-119-84(23)243-68-106-139(221)181-97(54-87-57-160-69-165-87)133(215)187-105(67-242-85(24)120(152(234)188-106)194-125(207)82(21)170-151(119)233)140(222)184-100(62-199)136(218)192-116(77(16)30-3)149(231)183-98(55-88-58-161-70-166-88)134(216)189-113(73(10)11)146(228)168-80(19)123(205)178-94(154(236)237)42-35-38-48-157/h32,57-58,69-79,82-86,90-107,112-121,199H,19-20,28-31,33-56,59-68,155-157,159H2,1-18,21-27H3,(H2,158,200)(H,160,165)(H,161,166)(H,162,208)(H,163,225)(H,164,227)(H,167,201)(H,168,228)(H,169,230)(H,170,233)(H,171,203)(H,172,202)(H,173,226)(H,174,210)(H,175,219)(H,176,213)(H,177,229)(H,178,205)(H,179,204)(H,180,206)(H,181,221)(H,182,220)(H,183,231)(H,184,222)(H,185,209)(H,186,214)(H,187,215)(H,188,234)(H,189,216)(H,190,232)(H,191,217)(H,192,218)(H,193,223)(H,194,207)(H,195,211)(H,196,212)(H,197,224)(H,236,237)/b89-32-/t75-,76-,77-,78-,79-,82-,83-,84-,85-,86-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-/m0/s1
Standard InChI Key: UBGQKVSEJLCTRB-WNQVXCOFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3566.43 | Molecular Weight (Monoisotopic): 3563.6977 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Zaschke-Kriesche J, Reiners J, Lagedroste M, Smits SHJ.. (2019) Influence of nisin hinge-region variants on lantibiotic immunity and resistance proteins., 27 (17): [PMID:31331652] [10.1016/j.bmc.2019.07.014] |
Source(1):